{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004190","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.191751+00:00","generated_at":"2026-06-20T17:59:46.546765+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Spero reports preliminary cash of ~$109M as of Dec 31, 2022; updates investor presentation","bullets":["Preliminary cash, cash equivalents and marketable securities of ~$109M as of Dec 31, 2022 (unaudited, subject to change).","Updated investor presentation highlights SPR720 as a potential first-line oral therapy for NTM infections.","Partnerships for tebipenem HBr and SPR206 are noted to support a strong balance sheet.","Audited FY2022 financials are not yet available; preliminary estimate may differ materially."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004190","json":"https://secwatch.observer/filing/0001193125-23-004190.json","markdown":"https://secwatch.observer/filing/0001193125-23-004190.md","text":"https://secwatch.observer/filing/0001193125-23-004190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523004190/0001193125-23-004190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523004190/d411727d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:59:46.546765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}